© 1998 American Heart Association, Inc.
Original Contributions |
The HMG-CoA Reductase Inhibitor Atorvastatin Increases the Fractional Clearance Rate of Postprandial Triglyceride-Rich Lipoproteins in Miniature Pigs
From the Department of Medicine and The John P. Robarts Research Institute, University of Western Ontario, London, Ontario, Canada (J.R.B., D.B.M., D.E.T, S.J.K., M.W.H.), and the Departments of Bioengineering and Medicine, University of Washington, Seattle (P.H.R.B., P.V.).
Correspondence to Murray W. Huff, The John P. Robarts Research Institute, 4-16, University of Western Ontario, 100 Perth Dr, London, Ontario N6A 5K8, Canada. E-mail mhuff{at}julian.uwo.ca
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—We have previously shown in vivo that the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin decreases hepatic apolipoprotein B (apoB) secretion into plasma. To test the hypothesis that atorvastatin modulates exogenous triglyceride-rich lipoprotein (TRL) metabolism in vivo, an oral fat load (2 g fat/kg body wt) containing retinol (50 000 IU) was given to 6 control miniature pigs and to 6 animals after 28 days of treatment with atorvastatin 3 mg · kg-1 · d-1. A multicompartmental model was developed by use of SAAM II and kinetic analysis performed on the plasma retinyl palmitate (RP) data. Peak TRL (d<1.006 g/mL; Sf>20) triglyceride concentrations were decreased 29% by atorvastatin, and the time to achieve this peak was delayed (5.2 versus 2.3 hours; P<0.01). The TRL triglyceride 0- to 12-hour area under the curve was decreased by 24%. In contrast, atorvastatin treatment had no effect on peak TRL RP concentrations, time to peak, or its rate of appearance into plasma; however, the TRL RP 0- to 12-hour area under the curve was decreased by 20%. Analysis of the RP kinetic parameters revealed that the TRL fractional clearance rate was increased significantly, 1.4-fold (3.093 versus 2.276 pools/h; P=0.012), with atorvastatin treatment. The percent conversion of TRL RP from the rapid-turnover to the slow-turnover compartment was decreased by 47% with atorvastatin treatment. The TRL RP fractional clearance rate was negatively correlated with very low density lipoprotein apoB production rate measured in the fasting state (r=-0.49). Thus, although atorvastatin had no effect on intestinal TRL assembly and secretion, plasma TRL clearance was significantly increased, an effect that may relate to a decreased competition for removal processes by hepatic very low density lipoprotein.
Key Words: HMG-CoA reductase inhibitor • atorvastatin • triglyceride-rich lipoproteins • tracer kinetics • compartmental model
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Chylomicrons are large, triglyceride-rich, apolipoprotein (apo) B-48–containing lipoproteins that are synthesized and secreted by the enterocyte to transport dietary fat to peripheral tissues. In contrast, VLDLs contain apoB-100 and transport hepatically synthesized triglycerides to their sites of utilization in the peripheral tissues. The assembly and secretion of apoB-containing lipoproteins from the enterocyte and hepatocyte are both complex processes; however, they involve a number of similar steps, as suggested by the absence of both chylomicrons and VLDLs from the plasma of subjects with abetalipoproteinemia.1 In the peripheral circulation, both chylomicrons and VLDLs share a saturable common metabolic removal pathway catalyzed by the hydrolytic enzyme lipoprotein lipase (LPL).2 3 4 5 Furthermore, the metabolic end products of the lipolytic process, chylomicron remnants6 and LDLs,7 are cleared from the plasma predominantly by hepatic receptor–mediated processes.
There is increasing evidence from cell culture studies in vitro8 9 and human studies in vivo10 11 12 13 14 15 that postprandial, triglyceride-rich, apoB-containing lipoproteins are atherogenic. Furthermore, these postprandial lipoproteins may be more closely related to atherogenic risk than those lipoproteins in the fasting state. Consequently, the measurement of postprandial lipids and lipoproteins may be superior to fasting lipid analyses in predicting the existence and/or progression of coronary heart disease.
The most commonly used approach for studying chylomicron
metabolism is an indirect one, involving the oral
administration of vitamin A (retinol) to endogenously label
intestinally derived triglyceride-rich lipoproteins
(TRLs).16 The rationale is that retinol is taken
up by enterocytes, esterified to retinyl esters [predominantly retinyl
palmitate (RP)], incorporated along with other neutral lipids into the
core of the chylomicron,17 and secreted into the
lymphatics. The assumption that the retinyl esters remain associated
with the chylomicron remnant, however, may not be entirely correct.
Krasinski et al18 found in humans that during the
late postprandial period (
9 hours), up to one third of the remaining
plasma RP was associated with HDL and LDL. Nevertheless, RP data
provide a close approximation of plasma chylomicron and chylomicron
remnant metabolism during the early postprandial period.
The plasma concentrations of retinyl esters with time reflect the
balance between (1) the assembly and secretion of chylomicrons into
plasma and (2) the formation and clearance of chylomicron remnants.
Most studies to date have used the areas under the retinyl ester curves
to determine differences in the kinetics of intestinally derived
retinyl esters in the postprandial state. However, this approach does
not allow one to distinguish the secretion rate from the clearance
rate.
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, an endoplasmic reticulum (ER) protein, catalyzes the rate-determining reductive deacylation of HMG-CoA to mevalonate7 19 in cholesterol biosynthesis. A class of lipid-lowering compounds, the HMG-CoA reductase inhibitors, have been shown to interfere with the rate-limiting step in cholesterol biosynthesis.20 These compounds are potent LDL cholesterol–lowering agents; however, relative to the LDL response, their ability to reduce triglyceride concentrations is modest. Moreover, the effects of HMG-CoA reductase inhibitors on hepatic apoB secretion in humans are inconsistent and have been the focus of a recent review by Huff and Burnett.21
As reviewed by Cohn,22 many studies have examined the effect of HMG-CoA reductase inhibitors on postprandial lipoprotein metabolism.23 24 25 26 27 28 29 30 Although the HMG-CoA reductase inhibitors as a class tend to decrease postprandial triglyceride concentrations, the effects of treatment are inconsistent but appear to correlate with the degree of fasting plasma triglyceride reduction.22 No multicompartmental modeling of any retinyl ester kinetic data, however, was performed in any of these studies.
Atorvastatin is a new synthetic, chiral, tissue-selective inhibitor of HMG-CoA reductase.31 32 Clinical trials of atorvastatin in humans have demonstrated marked plasma LDL cholesterol and triglyceride reductions.33 34 35 We have previously shown in vivo that inhibition of HMG-CoA reductase by atorvastatin in miniature pigs significantly decreases hepatic apoB-containing lipoprotein secretion into plasma in the fasting state,36 with minimal effect on rate of clearance.
We have now developed a multicompartmental model of TRL metabolism and have used kinetic analysis to determine the metabolic parameters of postprandial exogenous TRL in plasma with atorvastatin treatment. These studies were designed to test the hypothesis that the inhibition of cholesterol biosynthesis by atorvastatin modulates exogenous TRL metabolism in vivo.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animals and Diets
Miniature pigs weighing 22 to 25 kg were obtained from a local supplier (Premier Quality Genetics Inc, West Lorne, Ontario). After being acclimatized for 1 week, animals were maintained on the experimental diet for 28 days before the postprandial studies. Pigs were studied in pairs, with each pair being same-sex littermates. Each animal received a 590-g ration of diet (B.W.S. Hog Grower, B-W Feed and Seed Ltd) supplemented with lard, butter, and safflower oil (1:0.6:0.2), generating a final polyunsaturated/monounsaturated/saturated fatty acid ratio of 1:1:1. Cholesterol (Fisher Scientific) was added to the diet to a final concentration of 0.1% (0.2 mg/kcal). This diet provided 34% of calories from fat, 49% as carbohydrate, and 17% as protein.
Six animals received the HMG-CoA reductase inhibitor
atorvastatin (Parke-Davis) at a dose of 
3 mg · kg body
wt-1 · d-1 (80
mg/d) for 28 days before postprandial studies. This dose is equivalent
to the maximum therapeutic dose used in humans but is 2.6-fold
greater than that used in humans when body weight is taken into
consideration. Atorvastatin is a synthetic inhibitor of
HMG-CoA reductase with an in vitro IC50 of 7.5
nmol/L for rat liver microsomal HMG-CoA reductase
activity.37 The chemical structure of
atorvastatin has been illustrated previously.38
Atorvastatin was placed in gelatin capsules and, to ensure ingestion,
was administered by hand before the daily feeding. The 6 control
animals received a placebo capsule. The atorvastatin was given at 9
AM each day after a 24-hour fast.
Two weeks before the postprandial studies, an indwelling silicone elastomer (Silastic) catheter (1.96-mm ID) was surgically implanted in an external jugular vein.39 Isoflurane USP (Abbott Laboratories Ltd) was used as the anesthetic and ketamine USP (Vetrepharm Canada Inc) as the preanesthetic. Catheters that were kept patent by being filled with 7% EDTA-Na2 allowed blood sampling throughout each postprandial study in unrestrained, unanesthetized animals. The Animal Care Committee of the University of Western Ontario approved the experimental protocol.
Oral Fat Tolerance Test
After a 24-hour fast, pigs were fed the diet described above in
an amount calculated to provide 2 g fat/kg body wt and either
placebo or atorvastatin. This test meal was supplemented with 50 000
IU of retinol (vitamin A capsules USP, Novopharm Ltd) and
consumed within 10 minutes. The animals were not fed for the 12 hours
of the study but had free access to drinking water. Venous blood
samples (20 mL) were drawn at 0 (before the test meal), 0.5, 1, 1.5, 2,
2.5, 3, 4, 5, 6, 8, and 12 hours and collected into tubes containing
EDTA-Na2. Samples were kept on ice before
isolation of plasma lipoproteins and protected from light during
processing. Plasma was obtained by centrifugation at
1000g for 25 minutes at 4°C. The isolated plasma underwent
preparative ultracentrifugation at d=1.006
g/mL in a Beckman 50.4 Ti rotor at 35 500 rpm at 12°C for 16 hours.
TRL fractions (d<1.006 g/mL; Sf>20)
were isolated by tube slicing, and each plasma sample and TRL fraction
was analyzed for cholesterol,
triglyceride, and retinyl ester concentrations.
Retinyl Ester Analysis
Retinyl ester (RP and retinyl stearate) concentrations were
determined in total plasma and in the TRL fraction by a modification of
the high-performance liquid chromatography
(HPLC) method of Weintraub et al.40 Extractions
and analyses were carried out with HPLC-grade solvents and
under subdued light. Retinyl acetate was added to the samples as an
internal standard, and retinyl esters were extracted by a mixture of
ethanol, hexane, and water (1:5:0.5). The hexane layer was evaporated
under nitrogen. The samples were redissolved in ethanol and separated
on a 5-µm Hypersil C18 (7.5x0.32 cm) column. Pump A consisted of
88% methanol in water, whereas pump B consisted of 75% methanol and
25% isopropanol. Pump A was used at 100% for the first 4 minutes,
reduced to 20% pump A to 9 minutes, and further reduced to 0% pump A
to 12 minutes, at a flow rate of 0.6 mL/min. The absorbance of the
eluent was measured at 325 nm, and the retinyl ester concentrations
were quantified by ratio of peak height to that of the internal
standard. Areas under curves (AUCs) for the retinyl ester were
calculated. Within-assay and between-assay coefficients of variation
for TRL RP were <4.0% and <8.6%, respectively.
Retinyl Ester Kinetic Analysis
A compartmental model of TRL metabolism was
developed by use of the multicompartmental modeling program SAAM II
(SAAM Institute Inc, Seattle, WA) running on a Pentium-based personal
computer. The model was developed assuming that the fractional rate
constants (k) were time invariant and first order. The model
chosen to describe the data is shown in Figure 1
. This model is locally
identifiable41 42 in that it has, a priori,
1 solution for k(2,1) and k(0,3) but 2 distinct
solutions for k(0,4) and k(4,3). One of the 2
solutions for k(4,3) is consistently negative and
therefore must be rejected (all transfer constants must be positive).
Thus, the model is uniquely identifiable, with the constraint that all
of the transfer rates must be positive. Dietary retinol was used to
endogenously label intestinally derived TRL with RP.
|
Figure 1
shows the compartments of the model and the pathways that
connect the compartments. Compartment 1 represents the dosing
compartment. On the basis of earlier studies,43
it was assumed that all of the ingested retinol appeared in
chylomicrons as RP. Compartment 2, the delay compartment, contains 5
compartments in series. It was assumed that the residence time of
material in compartment 1 and in the delay compartments (compartment 2)
were equal. The functions of these compartments were to provide a delay
that corresponded to the time required for the synthesis of
chylomicrons and their secretion into plasma. From the delay
compartment, material enters compartment 3, which is assumed to
represent a rapid-turnover chylomicron pool. Chylomicrons in
compartment 3 are either removed from plasma or converted to a
slower-turnover plasma pool, compartment 4. Chylomicrons and
chylomicron remnants in compartment 4 are subsequently removed from
plasma. The sum of compartments 3 and 4 represents total plasma
TRL RP.
The compartmental model was fit to each individual data set. Simplifying the model to 1 plasma chylomicron pool clearly demonstrated the necessity for the more complex model structure to describe the tail component of the data. We were unable, however, to obtain acceptable coefficients of variation for any of the kinetic parameters reported for animal 3 in the atorvastatin-treated group. The experimental data for this animal did not fit the proposed model, presumably for technical reasons, and this pig represents an outlier relative to the whole population and was thus excluded from subsequent analysis.
Relationship Between TRL Fractional Clearance Rate (FCR) and
Fasting Hepatic VLDL ApoB Synthetic Rates
To examine the relationship between the kinetics of postprandial
retinyl esters and those of fasting hepatic apoB synthesis, 11 pigs (6
control and 5 atorvastatin-treated) participated in both an oral fat
load study and an apoB kinetic study using simultaneous
triple-isotope (131I-labeled
VLDL,125I-labeled LDL, and
3H-labeled leucine) labeling. These pigs
represent a subset of those reported
previously.36 The 2 protocols were performed 1
week apart.
Plasma Lipids and Lipoproteins
Cholesterol and triglyceride
concentrations were determined in the plasma and the TRL fraction by
enzymatic, colorimetric assays using reagents obtained
from Boehringer Mannheim GmbH. Areas under the
triglyceride curves were calculated. Lipoprotein protein
was determined by the method of Markwell et al.44
Tests for statistical significance of differences in lipid and RP
concentrations and kinetic parameters were compared by
unpaired t test. A value of P<0.05 was
considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The effect of atorvastatin on fasting plasma lipids and lipoproteins are shown in Table 1
.
Atorvastatin treatment significantly reduced fasting total plasma
cholesterol, triglyceride, and VLDL
triglyceride concentrations by 16% (P=0.021),
24% (P=0.003), and 34% (P=0.0007),
respectively. VLDL cholesterol was reduced by 26%
(P=0.074).
|
During the course of the oral fat tolerance test, plasma
cholesterol did not change significantly from baseline, at
any time point, in either the control or the treatment group (Figure 2). TRL cholesterol was
maximally lowered by 37% in the atorvastatin-treated animals at 2
hours, but this was not statistically significant
(P=0.143).
|
indicates atorvastatin; 
,
control.
Atorvastatin treatment resulted in a significant decrease in both
plasma and TRL triglycerides at 2 and 2.5 hours. The 0- to
12-hour AUC for plasma and TRL triglycerides decreased by
20% (Figure 3; Table 2) and 24%, respectively, in the
atorvastatin-treated animals; however, these reductions were not
statistically significant. Moreover, the peak TRL
triglyceride concentration was decreased 29%, and the time
to achieve this peak was delayed (5.2 versus 2.3 hours;
P<0.01). Consistent with the decrease in peak TRL
triglyceride, a decrease in the ratio of TRL
triglyceride to protein at the 2-hour time point was
observed in all atorvastatin-treated animals. However, this 23%
decrease was not statistically significant (P=0.081; Table 3).
|
|
|
The 0- to 12-hour AUC for plasma and TRL RP decreased by 16%
(P=0.047; Figure 4) and 15%
(P=0.193), respectively. When total plasma retinyl esters
were compared, similar differences were observed. No significant
differences were seen in either plasma or TRL retinyl esters for any
single time point between the control and treatment groups.
|
A fit of the model to the TRL RP data using the parameters
derived from the kinetic analysis for a
representative atorvastatin-treated animal is shown in
Figure 5. A fit of the model to the mean
TRL RP data using the parameters derived from the kinetic
analysis is shown in Figure 6.
The fractional rate constants, delay times, and FCRs derived from the
model analyses are shown in Table 4. The TRL RP k(4,3) between
the rapid-turnover and slow-turnover plasma compartments was decreased
by 78% (0.306 versus 1.074 pools/h; P=NS) with atorvastatin
treatment. The TRL RP FCR was increased by 1.4-fold in the
atorvastatin-treated pigs (3.093 versus 2.276 pools/h;
P=0.012). The percent conversion of TRL RP from the
rapid-turnover to the slow-turnover compartment decreased markedly, by
47% (P=NS), with atorvastatin treatment. The TRL RP FCR was
inversely correlated with the change in VLDL apoB production
rate (r=-0.49) for the 11 animals for which fasting apoB
kinetic data were also determined (Figure 7). However, the observed relationship
was not statistically significant.
|
|
|
|
Because the chylomicron pool size is changing with respect to time, it
is not possible to determine absolute secretion rates. Each pig in the
study received the same dose of retinol, and we have made the
assumption that the amount of retinol per TRL particle secreted was the
same for the control and treatment animals. However, 3 lines of
evidence suggest no significant change in the number of intestinal
particles assembled and secreted into plasma with atorvastatin
treatment. First, the TRL RP curves overlapped during the first 1.5
hours (Figure 4). Second, the TRL RP peak heights and times to peak
coincided in both the control and treatment animals. Third, the
integral of the mass in compartment 2 provides a time course for the
accumulation of the dose in the plasma. We can predict from the model
that the time required for 50% of the retinol to appear in the plasma
was unaffected by atorvastatin treatment (1.94 versus 1.98 hours;
P=NS).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present experiments were designed to test the hypothesis that inhibition of cholesterol biosynthesis by the potent HMG-CoA reductase inhibitor atorvastatin modulates exogenous TRL metabolism in vivo. These experiments were carried out in miniature pigs fed a fat- and cholesterol-containing diet and either placebo (control) or atorvastatin 3 mg · kg-1 · d-1 (80 mg/d) for 28 days before the postprandial studies. These studies used retinol, given with an oral fat load, to endogenously label chylomicrons and their remnants. The results obtained in a multicompartmental model clearly demonstrate that atorvastatin treatment significantly increases the clearance of postprandial TRLs from plasma but has no apparent effect on exogenous TRL synthesis and secretion. The major findings were that atorvastatin treatment (1) significantly decreased fasting cholesterol, triglyceride, and VLDL triglyceride concentrations in plasma; (2) decreased the 0- to 12-hour TRL RP AUC; (3) increased TRL RP FCR; and (4) decreased the percent conversion from the rapid-turnover plasma compartment to the slow-turnover plasma compartment. Furthermore, the TRL RP FCR was negatively correlated with the VLDL apoB production rate.
We have demonstrated previously in miniature pigs that atorvastatin treatment decreases fasting cholesterol, triglyceride, and VLDL triglyceride concentrations in plasma36 ; similar responses have been reported in human subjects.33 34 35 In the present study, decreases were seen in postprandial TRL cholesterol, triglyceride, and RP concentrations. The shapes of the TRL cholesterol and triglyceride curves were similar, with a reduced AUC during the first 4 hours of the study in atorvastatin-treated animals but overlapping curves during the final 8 hours of the study. In contrast, the TRL RP curves were overlapping during the first 1.5 hours after the fat meal, with the atorvastatin-treated pigs having lower values than control animals at the latter time points. The rate at which plasma triglycerides increase after a fat meal is a function of gastric emptying, intestinal absorption, chylomicron assembly and secretion, and LPL-mediated catabolism. However, the increase in postprandial triglycerides may not be entirely of intestinal origin, because recent studies have shown that hepatogenous VLDL triglycerides contribute appreciably to the TRL triglyceride response, particularly after the peak.11 45 46 47 48 As discussed below, this may be due to enhanced competition for VLDL triglyceride clearance by postprandial chylomicrons.
Our findings of decreased postprandial RP concentrations, most noticeable at the latter time points, are consistent with those found by Castro Cabezas et al25 in familial combined hyperlipidemic subjects treated with simvastatin (mean dose, 24.5 mg/d), Weintraub et al23 in type IIb subjects treated with lovastatin (80 mg/d), Gylling et al28 in type III (apoE2/2) hyperlipoproteinemic subjects treated with lovastatin (40 mg/d), and Simo et al26 in subjects with mild to moderate hypertriglyceridemia (1.75 to 7.5 mmol/L) and low HDL (<0.9 mmol/L) treated with lovastatin (40 mg/d). These reductions were associated with a mean reduction of 23% for the plasma RP AUC in these 4 studies. Statistically significant reductions of RP were achieved only in the studies by Weintraub at al23 for plasma, Sf>1000, and Sf<1000 0- to 24-hour AUCs and Castro Cabezas et al25 for the Sf<1000 0- to 24-hour AUC. However, the mechanism for the decreased AUCs could not be determined, because multicompartmental modeling was not carried out.
Although a large number of studies have investigated postprandial lipoprotein metabolism, as reviewed by Cohn,22 few have undertaken multicompartmental modeling to analyze chylomicron metabolism.43 49 50 51 52 53 To further investigate the apparent enhanced clearance of TRL RP, we developed a multicompartmental model of TRL metabolism, 2 compartments of which represent the total plasma TRL RP. We found that the TRL RP FCR was increased by 1.4-fold with atorvastatin treatment. Furthermore, the percent conversion of RP from the rapid-turnover plasma compartment to the slow-turnover plasma compartment was decreased, by 26%, in atorvastatin-treated pigs. Although Martins et al,54 using lipid emulsions in rats, demonstrated that particle number is an important factor regulating the metabolism of chylomicrons and their remnants, we did not find any evidence for a difference in chylomicron secretion with atorvastatin treatment. The TRL RP curves overlapped during the first 1.5 hours, and TRL RP peak heights and times to peak coincided in both the control and treatment animals.
The mechanism whereby the liver rapidly and specifically removes chylomicron remnants is still unclear. The hepatic uptake of chylomicron remnants has been shown to be mediated by the LDL receptor and LDL receptor–related protein (LRP),55 56 57 58 59 and turnover studies suggest that the liver is the main site of chylomicron metabolism.60 Various possible ligand proteins, including apoE, LPL, and hepatic lipase, have been proposed.61 Heparan sulfate proteoglycans (HSPGs) have been shown to enhance chylomicron clearance.62 63 The VLDL receptor has been implicated in chylomicron remnant removal by nonhepatic tissues.64 65 We have previously shown that inhibition of cholesterol synthesis by atorvastatin decreases both VLDL and LDL apoB production rates in the miniature pig.36 In these studies, neither the VLDL apoB FCR nor LDL apoB FCR was significantly affected by atorvastatin treatment. Furthermore, hepatic or intestinal LDL receptor mRNA abundances, as measured by RNase protection assay, were also unchanged. Our results in this animal model would suggest that upregulation of LDL receptors is not the reason for the enhanced TRL clearance. We could not exclude the possibility of an effect of atorvastatin treatment on LRP or VLDL receptor expression.
Our results differ from those of other postprandial studies using HMG-CoA reductase inhibitors, in that we demonstrated reductions in postprandial TRL triglycerides in the early postprandial period (0 to 4 hours). In contrast to the studies by Simo et al26 and Castro Cabezas et al,25 in which the reduced triglyceride concentrations observed at baseline were maintained throughout the duration of the study, the differences we observed in the postprandial period with atorvastatin treatment were greater than the differences observed at baseline and were confined to the first 4 hours in the postprandial period. This may represent a unique effect of atorvastatin treatment.
The decrease in TRL triglyceride seen in the early (0 to 4
hours) postprandial phase presumably represents a change in
lipoprotein composition of postprandial intestinal and/or hepatic
lipoproteins with atorvastatin treatment. Consistent with the
decrease in peak TRL triglyceride, a trend toward a
decrease (23%) in the ratio of TRL triglyceride to protein
at the 2-hour time point was observed with atorvastatin treatment
(Table 3). It is possible that atorvastatin treatment results in the
secretion of a chylomicron particle with (1) a reduced triglyceride
content and/or (2) an altered apolipoprotein composition, thereby
allowing a more rapid rate of lipolysis and subsequent hepatic
clearance of triglyceride-depleted remnants.
Postprandial apolipoproteins, particularly apoC and apoE, and lipid compositional changes in chylomicrons, their remnants, and VLDL, have been demonstrated in humans by immunoaffinity chromatography.66 67 ApoC-III, a component of chylomicrons and VLDL, has been shown to play an important role in TRL metabolism. In vitro, apoC-III can inhibit the hydrolysis of triglyceride68 69 and reduce TRL clearance.70 71 In vivo, transgenic mice overexpressing human apoC-III develop a marked hypertriglyceridemia resulting from impaired clearance of TRL due to apoE insufficiency.72 73 In contrast, homozygous apoC-III knockout mice have hypotriglyceridemia and enhanced TRL clearance.74 ApoE-enriched subfractions of large VLDL from hypertriglyceridemic subjects show enhanced triglyceride hydrolysis by LPL.75 ApoE is important for the hepatic recognition of TRL remnants by the LDL receptor,76 the LRP,55 59 and HSPGs.62 HSPGs play a significant role in plasma clearance and hepatic uptake of TRL remnants in mice.63 It is possible that atorvastatin treatment decreases apoC-III and/or increases apoE concentrations of TRL. However, in the present study, TRL apoC-III and apoE concentrations were not determined.
Large TRLs, and in particular chylomicrons, are the favored substrates for LPL. Essentially all TRLs share the same lipolytic pathway, that is, the hydrolysis of the core triglyceride content by LPL. After a fat meal, chylomicrons and endogenous TRLs of hepatic origin (VLDL) are mixed in blood and can compete for LPL. It has been shown that endogenous TRLs accumulate in plasma after oral fat intake11 47 48 because of the failure of these lipoproteins to effectively compete with chylomicrons for lipolysis by LPL.2 3 4 5 We have established that in the fasting state, atorvastatin treatment of miniature pigs decreases the production rate of hepatic VLDL apoB.36 Assuming that atorvastatin continued to decrease hepatic VLDL apoB secretion in the postprandial state, the enhanced fractional clearance of intestinally derived TRL observed with atorvastatin treatment would be consistent with decreased competition for removal processes by hepatic VLDL. A negative correlation was observed between TRL (d<1.006 g/mL; Sf>20) RP FCR and VLDL apoB production rate (r=-0.49; P=NS) in the 11 animals in which both protocols had been carried out. Consistent with this observation, Le et al,51 in a group of normolipidemic controls and hypertriglyceridemic subjects, found a positive correlation between the production rate for VLDL apoB in the fasting state and the half-life (the inverse of FCR) of retinyl esters in both Sf 20 to 400 (mostly remnants) and Sf>400 lipoproteins.
In conclusion, we have demonstrated in a multicompartmental model of TRL metabolism that the inhibition of HMG-CoA reductase by atorvastatin has no significant effect on intestinal TRL assembly and secretion; however, plasma clearance of TRL was increased, perhaps related to decreased competition for removal processes by hepatic VLDL.
|
Acknowledgments |
|---|
This work was supported by grants from the Heart and Stroke Foundation of Ontario (T-3371) to Dr Huff; from the National Institutes of Health, NHLBI, HL-49110 to Dr Barrett and NCRR RR-02176 to Drs Barrett and Vicini; and from Parke-Davis, Canada to Dr Huff. Dr Burnett was a recipient of a Heart and Stroke Foundation of Canada Research Fellowship, Dr Miller was a recipient of a Heart and Stroke Foundation of Ontario Research Fellowship, and Dr Huff is a Career Investigator of the Heart and Stroke Foundation of Ontario. We thank Tim Welke for his technical assistance, Kim Wood for performing the surgeries, and Dr Roger S. Newton for kindly providing the atorvastatin. The software for testing a priori identifiability is distributed by Gruppo Biomed Mod, Padova, Italy (for more information, contact Professor Claudio Cobelli at cobelli@dei.unipd.it).
Received December 15, 1997; accepted May 26, 1998.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Wetterau JR, Aggerbeck LP, Bouma M, Eisenberg C, Munck A, Hermier M, Schmitz J, Gay G, Rader DJ, Gregg RE. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science. 1992;258:999–1001.
2. Brunzell JD, Hazzard WR, Porte D Jr, Bierman EL. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest. 1973;52:1578–1585.
3.
Robins SJ, Fasulo JM, Robins VF, Patton GM. Response
of serum triglycerides of endogenous origin to
the administration of triglyceride-rich lipid particles.
Am J Physiol. 1989;257:E860–E865.
4. Karpe F, Hultin M. Endogenous triglyceride-rich lipoproteins accumulate in rat plasma when competing with a chylomicron-like triglyceride emulsion for a common lipolytic pathway. J Lipid Res. 1995;36:1557–1566.[Abstract]
5. Björkegren J, Packard CJ, Hamsten A, Bedford D, Caslake M, Foster L, Shepherd J, Stewart P, Karpe F. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J Lipid Res. 1996;37:76–86.[Abstract]
6. de Faria E, Fong LG, Komaromy M, Cooper AD. Relative roles of the LDL receptor, the LDL receptor-like protein, and hepatic lipase in chylomicron remnant removal by the liver. J Lipid Res. 1996;37:197–209.[Abstract]
7.
Brown MS, Goldstein JL. A receptor-mediated pathway
for cholesterol homeostasis. Science. 1986;232:34–47.
8. Floren CH, Albers JJ, Bierman EL. Uptake of chylomicron remnants causes cholesterol accumulation in cultured human arterial smooth muscle cells. Biochim Biophys Acta. 1981;663:336–349.[Medline] [Order article via Infotrieve]
9.
Huff MW, Evans AJ, Sawyez CG, Wolfe BM, Nestel
PJ. Cholesterol accumulation in J774
macrophages induced by triglyceride-rich
lipoproteins: comparison of very low density lipoprotein from subjects
with type III, IV, and V hyperlipoproteinemias.
Arterioscler Thromb. 1991;11:221–233.
10.
Patsch JR, Miesenböck G, Hopferwieser T,
Muhlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W. Relation of
triglyceride metabolism and coronary
artery disease: studies in the postprandial state. Arterioscler
Thromb. 1992;12:1336–1345.
11. Karpe F, Steiner G, Olivecrona T, Carlson LA, Hamsten A. Metabolism of triglyceride-rich lipoproteins during alimentary lipemia. J Clin Invest. 1993;91:748–759.
12. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 1994;106:83–97.[Medline] [Order article via Infotrieve]
13.
Ginsberg HN, Jones J, Blaner WS, Thomas A, Karmally
W, Fields L, Blood D, Begg MD. Association of postprandial
triglyceride and retinyl palmitate responses with newly
diagnosed exercise-induced myocardial ischemia in middle-aged
men and women. Arterioscler Thromb Vasc Biol. 1995;15:1829–1838.
14.
Weintraub MS, Grosskopf I, Rassin T, Miller H, Charach
G, Rotmensch HH, Liron M, Rubinstein A, Iaina A. Clearance of
chylomicron remnants in normolipidaemic patients with coronary
heart disease: case control study over three years. BMJ. 1996;312:935–939.
15. Meyer E, Westerveld HT, de Ruyter-Meijstek FC, van Greevenbroek MM, Reinks R, van Rijn HJ, Erkelens DW, de Bruin TW. Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case-control study. Atherosclerosis. 1996;124:221–235.[Medline] [Order article via Infotrieve]
16. Föger B, Patsch JR. Strategies and methods for the assessment of disturbed postprandial lipid metabolism. Curr Opin Lipidol. 1993;4:428–433.
17. Goodman DS, Blomstrand B, Werner B, Huang HS, Shiratori T. The intestinal absorption and metabolism of vitamin A and beta carotene in man. J Clin Invest. 1966;45:1615–1623.
18. Krasinski SD, Cohn JS, Russell RM, Schaefer EJ. Postprandial plasma vitamin A metabolism in humans: a reassessment of the use of plasma retinyl esters as markers for intestinally derived chylomicrons and their remnants. Metabolism. 1990;39:357–365.[Medline] [Order article via Infotrieve]
19. Hampton R, Dimster-Denk D, Rine J. The biology of HMG-CoA reductase: the pros of contra-regulation. Trends Biochem Sci. 1996;21:140–145.[Medline] [Order article via Infotrieve]
20. Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: a look back and a look ahead. Can J Cardiol. 1992;8:843–864.[Medline] [Order article via Infotrieve]
21. Huff MW, Burnett JR. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Curr Opin Lipidol. 1997;8:138–145.[Medline] [Order article via Infotrieve]
22. Cohn JS. Postprandial lipid metabolism. Curr Opin Lipidol. 1994;5:185–190.[Medline] [Order article via Infotrieve]
23. Weintraub MS, Eisenberg S, Breslow JL. Lovastatin reduces postprandial lipoprotein levels in hypercholesterolaemic patients with mild hypertri- glyceridaemia. Eur J Clin Invest. 1989;19:480–485.[Medline] [Order article via Infotrieve]
24. Cianflone K, Bilodeau M, Davignon J, Sniderman AD. Modulation of chylomicron remnant metabolism by an hepatic hydroxymethylglutaryl coenzyme A reductase inhibitor. Metabolism. 1990;39:274–280.[Medline] [Order article via Infotrieve]
25. Castro Cabezas M, de Bruin TWA, Kock LAW, Kortlandt W, van Linde-Sibenius Trip M, Jansen H, Erkelens DW. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. Metabolism. 1993;42:497–503.[Medline] [Order article via Infotrieve]
26. Simo IE, Yakichuk JA, Ooi TC. Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome. Atherosclerosis. 1993;100:55–64.[Medline] [Order article via Infotrieve]
27. Castro Cabezas M, Erkelens DW, Kock LAW, de Bruin TWA. Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides. Eur J Clin Invest. 1994;24:669–678.[Medline] [Order article via Infotrieve]
28. Gylling H, Relas H, Miettinen TA. Postprandial vitamin A and squalene clearances and cholesterol synthesis off and on lovastatin treatment in type III hyperlipoproteinemia. Atherosclerosis. 1995;115:17–26.[Medline] [Order article via Infotrieve]
29. Bhatnagar D, Durrington PN, Kumar S, Mackness MI, Dean J, Boulton AJM. Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes. 1995;44:460–465.[Abstract]
30. O'Keefe JH Jr, Harris WS, Nelson J, Windsor SL. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol. 1995;76:480–484.[Medline] [Order article via Infotrieve]
31. Baumann KL, Butler DE, Deering CF, Mennen KE, Millar A, Nanninga TN, Palmer CW, Roth BD. The convergent synthesis of CI-981, an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett. 1992;33:2283–2284.
32. Bocan TMA, Ferguson E, McNally W, Uhlendorf PD, Mueller SB, Dehart P, Sliskovic DR, Roth BD, Krause BR, Newton RS. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Biochim Biophys Acta. 1992;1123:133–144.[Medline] [Order article via Infotrieve]
33.
Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL,
Schwartz SL, Lupien P, Jones PH, Haber HE, Black DM. Reduction of LDL
cholesterol by 25% to 60% in patients with primary
hypercholesterolemia by atorvastatin, a new
HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc
Biol. 1995;15:678–682.
34.
Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon
J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske
LJ, Black DM. Efficacy and safety of a new HMG-CoA reductase
inhibitor, atorvastatin, in patients with
hypertriglyceridemia. JAMA. 1996;275:128–133.
35. Heinonen TM, Stein E, Weiss SR, McKenney JM, Davidson M, Shurzinske L, Black DM. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther. 1996;18:853–863.[Medline] [Order article via Infotrieve]
36.
Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ,
Barrett PHR, Newton RS, Huff MW. Inhibition of HMG-CoA reductase by
atorvastatin decreases both VLDL and LDL apoB production in
miniature pigs. Arterioscler Thromb Vasc Biol. 1997;17:2589–2600.
37. Roth BD, Bocan TMA, Blankley CJ, Chucholowski AW, Creger PL, Creswell MW, Ferguson E, Newton RS, O'Brien P, Picard JA, Roark WH, Sekerke CS, Sliskovic DR, Wilson MW. Relationship between tissue selectivity and lipophilicity for inhibitors of HMG-CoA reductase. J Med Chem. 1991;34:463–466.[Medline] [Order article via Infotrieve]
38. Bocan TMA, Mazur MJ, Mueller SB, Brown EQ, Sliskovic DR, O'Brien PM, Creswell MW, Lee H, Uhlendorf PD, Roth BD, Newton RS. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Atherosclerosis. 1994;111:127–142.[Medline] [Order article via Infotrieve]
39. Huff MW, Telford DE, Woodcroft K, Strong WLP. Mevinolin and cholestyramine inhibit the direct synthesis of low density lipoprotein apolipoprotein B in miniature pigs. J Lipid Res. 1985;26:1175–1186.[Abstract]
40. Weintraub MS, Eisenberg S, Breslow JL. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III and type IV hyperlipoproteinemic individuals: effects of treatment with cholestyramine and gemfibrozil. J Clin Invest. 1987;79:1110–1119.
41. Cobelli C, DiStefano JJ III. Parameter and structural identifiability concepts and ambiguities: a critical review and analysis. Am J Physiol. 1980;239:R7–R24.
42. Audoly S, D'Angio L, Saccomani MP, Cobelli C. Global identifiability of linear compartmental models: a computer algebra algorithm. IEEE Trans Biomed Eng. 1998;45:36–47.[Medline] [Order article via Infotrieve]
43. Cortner JA, Coates PM, Le N, Cryer DR, Ragni MC, Faulkner A, Langer T. Kinetics of chylomicron remnant clearance in normal and hyperlipoproteinemic subjects. J Lipid Res. 1987;28:195–206.[Abstract]
44. Markwell MAK, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 1978;87:206–210.[Medline] [Order article via Infotrieve]
45. Cohn JS, McNamara JR, Krasinski SD, Russell RM, Schaefer EJ. Role of triglyceride-rich lipoproteins from the liver and intestine in the etiology of postprandial peaks in plasma triglyceride concentration. Metabolism. 1989;38:484–490.[Medline] [Order article via Infotrieve]
46. Cohn JS, Johnson EJ, Millar JS, Cohn SD, Milne RW, Marcel YL, Russell RM, Schaefer EJ. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res. 1993;34:2033–2040.[Abstract]
47. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. J Lipid Res. 1988;29:925–936.[Abstract]
48.
Schneeman BO, Kotite L, Todd KM, Havel RJ. Relationship
between the responses of triglyceride-rich lipoproteins in
blood plasma containing apolipoproteins B-48 and B-100 to
fat-containing meal in normolipidemic humans. Proc Natl Acad Sci
U S A. 1993;90:2069–2073.
49. Berr F. Characterization of chylomicron remnant clearance by retinyl palmitate label in normal humans. J Lipid Res. 1992;33:915–930.[Abstract]
50. Hultin M, Savonen R, Olivecrona T. Chylomicron metabolism in rats: lipolysis, recirculation of triglyceride-derived fatty acids in plasma FFA, and fate of core lipids as analyzed by compartmental modelling. J Lipid Res. 1996;37:1022–1036.[Abstract]
51. Le N, Coates PM, Gallagher PR, Cortner JA. Kinetics of retinyl esters during postprandial lipemia in man: a compartmental model. Metabolism. 1997;46:584–594.[Medline] [Order article via Infotrieve]
52. Karpe F, Olivecrona T, Hamsten A, Hultin M. Chylomicron/chylomicron remnant turnover in humans: evidence for margination of chylomicrons and poor conversion of larger to smaller chylomicron remnants. J Lipid Res. 1997;38:949–961.[Abstract]
53.
Wolever TMS, Hegele RA, Connelly PW, Ransom TPP, Story
JA, Furumoto EJ, Jenkins DJA. Long-term effect of soluble-fiber foods
on postprandial fat metabolism in dyslipidemic
subjects with apo E3 and apo E4 genotypes. Am J Clin
Nutr. 1997;66:584–590.
54. Martins IJ, Mortimer B, Miller J, Redgrave TG. Effects of particle size and number on the plasma clearance of chylomicrons and remnants. J Lipid Res. 1996;37:2696–2705.[Abstract]
55.
Ishibashi S, Herz J, Maeda N, Goldstein JL, Brown MS.
The two-receptor model of lipoprotein clearance: tests of the
hypothesis in "knockout" mice lacking the low density lipoprotein
receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci
U S A. 1994;91:4431–4435.
56.
Willnow TE, Armstrong SA, Hammer RE, Herz J. Functional
expression of the low density lipoprotein-related protein is controlled
by receptor-associated protein in vivo. Proc Natl Acad Sci
U S A. 1995;92:4537–4541.
57.
Willnow TE, Sheng Z, Ishibashi S, Herz J.
Inhibition of hepatic chylomicron remnant uptake by gene transfer of a
receptor antagonist. Science. 1994;264:1471–1474.
58. Skottova N, Lookene A, Hultin M, Olivecrona G. Lipoprotein lipase enhances removal of chylomicrons and chylomicron remnants by the perfused rat liver. J Lipid Res. 1995;36:1334–1344.[Abstract]
59.
Ishibashi S, Perrey S, Chen Z, Osuga J, Shimada M,
Ohashi K, Harada K, Yazaki Y, Yamada N. Role of the low density
lipoprotein (LDL) receptor pathway in the metabolism of
chylomicron remnants: a quantitative study in knockout mice lacking the
LDL receptor, apolipoprotein E, or both. J Biol Chem. 1996;271:22422–22427.
60.
Hussain MM, Innerarity TL, Brecht WJ, Mahley RW.
Chylomicron metabolism in normal,
cholesterol-fed, and Watanabe heritable
hyperlipidemic rabbits: saturation of the sequestration
step of the remnant clearance pathway. J Biol Chem. 1995;270:8578–8587.
61.
Ji Z, Fazio S, Lee Y, Mahley RW. Secretion-capture role
for apolipoprotein E in remnant lipoprotein metabolism
involving cell surface heparan sulfate proteoglycans. J Biol
Chem. 1994;269:2764–2772.
62.
Ji Z, Brecht WJ, Miranda RD, Hussain MM, Innerarity TL,
Mahley RW. Role of heparan sulfate proteoglycans in the binding and
uptake of apolipoprotein E-enriched remnant lipoproteins by cultured
cells. J Biol Chem. 1993;268:10160–10167.
63. Ji Z, Sanan DA, Mahley RW. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J Lipid Res. 1995;36:583–592.[Abstract]
64. Niemeier A, Gåfvels M, Heeren J, Meyer N, Angelin B, Beisiegel U. VLDL receptor mediates the uptake of human chylomicron remnants in vitro. J Lipid Res. 1996;37:1733–1742.[Abstract]
65.
Takahashi S, Kawarabayasi Y, Nakai T, Sakai J, Yamamoto
T. Rabbit very low density lipoprotein receptor-like protein with
distinct ligand specificity. Proc Natl Acad Sci U S A. 1992;89:9252–9256.
66. Berr F, Eckel R, Kern F Jr. Plasma decay of chylomicron remnants is not affected by heparin-stimulated plasma lipolytic activity in normal fasting man. J Lipid Res. 1985;26:852–859.[Abstract]
67. Björkegren J, Hamsten A, Milne RW, Karpe F. Alterations of VLDL composition during alimentary lipemia. J Lipid Res. 1997;38:301–314.[Abstract]
68. Brown V, Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochim Biophys Acta. 1972;46:375–382.
69. Kinnunen PKJ, Ehnholm C. Effect of serum and C-apoproteins from very low density lipoproteins on human post-heparin plasma hepatic lipase. FEBS Lett. 1976;65:354–357.[Medline] [Order article via Infotrieve]
70. Shelbourne F, Hanks J, Meyers W, Quarfordt SA. Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat. J Clin Invest. 1980;65:652–658.
71. Windler E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res. 1985;26:556–563.[Abstract]
72. Aalto-Setälä K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh R, Ramakrishnan R, Ginsberg HN, Breslow JL. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice: diminished very low density lipoprotein fractional catabolic rate associated with increased apoCIII and reduced apoE on the particles. J Clin Invest. 1992;90:1889–1900.
73.
de Silva HV, Lauer SJ, Wang J, Simonet WS, Weisgraber
KH, Mahley RW. Overexpression of human apolipoprotein C-III in
transgenic mice results in an accumulation of apolipoprotein B48
remnants that is corrected by excess apolipoprotein E. J
Biol Chem. 1994;269:2324–2335.
74.
Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J.
Targeted disruption of the apolipoprotein C-III gene in mice results in
hypotriglyceridemia and protection from postprandial
hypertriglyceridemia. J Biol
Chem. 1994;269:23610–23616.
75. Evans AJ, Wolfe BM, Strong WLP, Huff MW. Reduced lipolysis of large apoE-poor very-low-density lipoprotein subfractions from type IV hypertriglyceridemic subjects in vitro and in vivo. Metabolism. 1993;42:105–115.[Medline] [Order article via Infotrieve]
76. Gianturco SH, Brown FB, Gotto AMJ, Bradley WA. Receptor-mediated uptake of hypertriglyceridemic very low density lipoproteins by normal human fibroblasts. J Lipid Res. 1982;23:984–993.[Abstract]
This article has been cited by other articles:
 |
|
 |
|
  A. J Tremblay, B. Lamarche, J.-C. Hogue, and P. Couture Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia J. Lipid Res., July 1, 2009; 50(7): 1463 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Basso, L. A. Freeman, C. Ko, C. Joyce, M. J. Amar, R. D. Shamburek, T. Tansey, F. Thomas, J. Wu, B. Paigen, et al. Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited J. Lipid Res., January 1, 2007; 48(1): 114 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bach-Ngohou, K. Ouguerram, R. Frenais, P. Maugere, B. Ripolles-Piquer, Y. Zair, M. Krempf, and J. M. Bard Influence of Atorvastatin on Apolipoprotein E and AI Kinetics in Patients with Type 2 Diabetes J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 363 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Castro Cabezas, C. Verseyden, S. Meijssen, H. Jansen, and D. W. Erkelens Effects of Atorvastatin on the Clearance of Triglyceride-Rich Lipoproteins in Familial Combined Hyperlipidemia J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 5972 - 5980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Verseyden, S. Meijssen, H. van Dijk, H. Jansen, and M. C. Cabezas Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia J. Lipid Res., November 1, 2003; 44(11): 2100 - 2108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. G. Parhofer, E. Laubach, and P. H. R. Barrett Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients J. Lipid Res., June 1, 2003; 44(6): 1192 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Guerin, P. Egger, W. Le Goff, C. Soudant, R. Dupuis, and M. J. Chapman Atorvastatin Reduces Postprandial Accumulation and Cholesteryl Ester Transfer Protein-Mediated Remodeling of Triglyceride-Rich Lipoprotein Subspecies in Type IIB Hyperlipidemia J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4991 - 5000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M van Dam, M Zwart, F de Beer, A H M Smelt, M H Prins, M D Trip, L M Havekes, P J Lansberg, and J J P Kastelein Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia Heart, September 1, 2002; 88(3): 234 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. G. Parhofer, P. H. R. Barrett, and P. Schwandt Atorvastatin Improves Postprandial Lipoprotein Metabolism in Normolipidemic Subjects J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4224 - 4230. [Abstract] [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||